Company / EPS (Diluted)
Lineage Cell Therapeutics, Inc. EPS (Diluted) History
FY2016-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest EPS (Diluted)
-$0.09
FY2025
5-year range
-$0.15 / -$0.09
FY2021-FY2025
Trend
+25.0%
vs FY2024
Sector context
Sector data unavailable
Latest sector comparison
What the data says
EPS (Diluted) has fluctuated over the past 9 years, ranging from $-0.59 in FY2017 to $-0.08 in FY2020.
Based on SEC 10-K filings.
-0.09 in FY2025.
Improved from $-0.15 to $-0.09 over the past 2 years.
EPS (Diluted) over time
Growth rates
- 3-Year CAGR
- -
- 5-Year CAGR
- -
- 10-Year CAGR
- -
Key checks
Key Insights
- In FY2025, eps (diluted) increased 25.0% year-over-year.
- Peak eps (diluted) was recorded in FY2020.
- Lowest eps (diluted) in the period was in FY2017.
Company context
Key Data Points
- Altman Z-Score -3.82 (distress zone, below 1.8 threshold)
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | EPS (Diluted)Value | YoY GrowthYoY |
|---|---|---|
| FY2025 | -$0.09 | +25.0% |
| FY2024 | -$0.12 | +20.0% |
| FY2023 | -$0.15 | - |
| FY2022 | - | - |
| FY2021 | -$0.14 | -75.0% |
| FY2020 | -$0.08 | +77.8% |
| FY2019 | -$0.36 | -111.8% |
| FY2018 | -$0.17 | +71.2% |
| FY2017 | -$0.59 | -7.3% |
| FY2016 | -$0.55 | +32.1% |
As of FY2025 · SEC 10-K · Updated Jun 24, 2026